Evidence map›Paper›PMID 42256355›Full record

ArticlePCN reports : psychiatry and clinical neurosciences2026

Clozapine-induced diarrhea: A case report and mechanistic overview.

Shahab Dastmardi, Soha Namazi

Abstract read
In one paragraph

Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shahab DastmardiFaculty of Pharmacy Tehran University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0009-0006-7579-2227
Soha NamaziDepartment of Clinical Pharmacy School of Pharmacy Tehran University of Medical Sciences Tehran Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clozapine is an atypical antipsychotic that is highly effective in managing treatment-resistant schizophrenia. However, its use is associated with a wide range of adverse effects, including agranulocytosis, seizures, sedation, and gastrointestinal issues such as constipation, and less commonly, diarrhea. While constipation is a well-documented side effect of clozapine, diarrhea induced by the drug remains underreported and poorly understood. Case Presentation: A 46-year-old male patient with treatment-resistant schizophrenia developed severe diarrhea, fever, and weight loss shortly after initiating clozapine at a dose of 100 mg three times daily (300 mg/day). These symptoms persisted until clozapine was discontinued, after which they resolved. When clozapine was reintroduced, the symptoms of diarrhea recurred, confirming that clozapine was the causative agent of the gastrointestinal distress. The patient's clinical condition improved once clozapine was discontinued again, highlighting the potential for severe gastrointestinal adverse effects associated with this medication. Conclusion: Clozapine remains a valuable treatment option for individuals with treatment-resistant schizophrenia, but clinicians should be aware of its potential to cause severe gastrointestinal adverse effects, including diarrhea. Early recognition of these side effects, appropriate diagnostic evaluation, and timely management are essential to ensure patient safety and optimize treatment outcomes. In cases where gastrointestinal symptoms are severe, discontinuation of clozapine may be necessary to resolve the issues and prevent further complications.

Indexed as

clozapineclozapine‐induced diarrheapharmacotherapyschizophrenia treatment

Identifiers

PMID42256355
PMCPMC13239329

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.